Subject(s)
Catheterization/instrumentation , Decompression, Surgical/instrumentation , Endosonography , Gastroscopy , Needles , Pneumoperitoneum/surgery , Postoperative Complications/surgery , Surgery, Computer-Assisted , Tomography, X-Ray Computed , Aged, 80 and over , Biopsy, Fine-Needle , Gastric Mucosa/surgery , Humans , Liver/pathology , Male , Pneumoperitoneum/diagnostic imaging , Postoperative Complications/diagnostic imaging , Reoperation , Stomach Neoplasms/surgeryABSTRACT
BACKGROUND AND STUDY AIMS: Endoscopic mucosal resection and photodynamic therapy are exciting, minimally invasive curative techniques that represent an alternative to surgery in patients with Barrett's esophagus and high-grade dysplasia or intramucosal adenocarcinoma. However, there is lack of uniformity regarding which staging method should be used prior to therapy, and some investigators even question whether staging is required prior to ablation. We report our experience with a protocol of conventional endoscopic ultrasound staging prior to endoscopic therapy. PATIENTS AND METHODS: A total of 25 consecutive patients with a diagnosis of high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus who had been referred to the University of Chicago for staging in preparation for endoscopic therapy between March 2002 and November 2004 were included in the study. All 25 patients underwent repeat diagnostic endoscopy and conventional endosonography with a radial echo endoscope. Any suspicious lymph nodes that were detected were sampled using endoscopic ultrasound-guided fine-needle aspiration. RESULTS: Baseline pathology in the 25 patients (mean age 70, range 49-85) revealed high-grade dysplasia in 12 patients and intramucosal carcinoma in 13 patients. Five patients were found to have submucosal invasion on conventional endosonography. Seven patients had suspicious adenopathy, six regional (N1) and one metastatic to the celiac axis (M1a). Fine-needle aspiration confirmed malignancy in five of these seven patients. Based on these results, five patients (20%) were deemed to be unsuitable candidates for endoscopic therapy. CONCLUSIONS: By detecting unsuspected malignant lymphadenopathy, conventional endosonography and endoscopic ultrasound with fine-needle aspiration dramatically changed the course of management in 20% of patients referred for endoscopic therapy of Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma. Based on our results, we believe that conventional endosonography and endoscopic ultrasound with fine-needle aspiration when nodal disease is present should be performed routinely in all patients referred for endoscopic therapy in this setting.
Subject(s)
Adenocarcinoma/pathology , Barrett Esophagus/pathology , Catheter Ablation/methods , Endoscopy, Gastrointestinal , Endosonography , Esophageal Neoplasms/pathology , Precancerous Conditions/pathology , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/surgery , Aged , Aged, 80 and over , Barrett Esophagus/diagnostic imaging , Barrett Esophagus/surgery , Biopsy, Fine-Needle/methods , Esophageal Neoplasms/diagnostic imaging , Esophageal Neoplasms/surgery , Female , Humans , Intestinal Mucosa/diagnostic imaging , Intestinal Mucosa/pathology , Male , Middle Aged , Precancerous Conditions/diagnostic imaging , Precancerous Conditions/surgery , Retrospective StudiesABSTRACT
Complications of endoscopic retrograde cholangiopancreatography (ERCP) that are associated with the guide wire are fortunately rare, but may be more common than is reported. We describe the case of a 43-year-old woman with obstructive jaundice from metastatic pancreatic cancer who underwent an elective ERCP for biliary stent placement. This was complicated by guide wire-associated injury that resulted in the development and eventual rupture of a subcapsular hepatic hematoma and which was successfully treated with nonsurgical management. If identified and treated rapidly, using a multidisciplinary approach (i. e., with medical, interventional radiology, and surgical input), such patients can be conservatively managed.
Subject(s)
Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Embolization, Therapeutic , Hematoma/etiology , Liver/injuries , Adult , Female , Hematoma/therapy , Hepatic Artery , Humans , Jaundice, Obstructive/etiology , Pancreatic Neoplasms/complications , Stents , Tomography, X-Ray ComputedABSTRACT
Fetuin/alpha2-HS glycoprotein (alpha2-HSG) homologs have been identified in several species including rat, sheep, pig, rabbit, guinea pig, cattle, mouse and human. Multiple physiological roles for these homologs have been suggested, including ability to bind to hydroxyapatite crystals and to specifically inhibit the tyrosine kinase (TK) activity of the insulin receptor (IR). In this study we report the identification, cloning, and characterization of the mouse Ahsg gene and its function as an IR-TK inhibitor. Genomic clones derived from a mouse Svj 129 genomic library were sequenced in order to characterize the intron-exon organization of the mouse Ahsg gene, including an 875 bp subclone containing 154 bp upstream from the transcription start site, the first exon, and part of the first intron. A second genomic subclone harboring a 3.45 kb Bgl II fragment contained exons 2, 3 and 4 in addition to two adjacent elements within the first intron-a repetitive element of the B1 family (92 bp) and a 271 bp tract of (T,C)n*(A,G)n. We have mapped mouse Ahsg at 16 cM adjacent to the Diacylglycerol kinase 3 (Dagk3) gene on chromosome 16 by genotyping interspecific backcross panels between C57BL/6J and Mus spretus. The position is syntenic with human chromosome 3q27, where the human AHSG gene resides. Using recombinant mouse alpha2-HSG expressed from a recombinant baculovirus, we demonstrate that mouse alpha2-HSG inhibits insulin-stimulated IR autophosphorylation and IR-TKA in vitro. In addition, mouse alpha2-HSG (25 microg/ml) completely abolishes insulin-induced DNA synthesis in H-35 rat hepatoma cells. Based on the sequence data and functional analysis, we conclude that the mouse Ahsg gene is the true ortholog of the human AHSG gene.
Subject(s)
Blood Proteins , Chromosome Mapping , Cystatins/genetics , Enzyme Inhibitors , Protein-Tyrosine Kinases/antagonists & inhibitors , alpha-Fetoproteins/genetics , Amino Acid Sequence , Animals , Base Sequence , Cloning, Molecular , Cystatins/chemistry , Cystatins/pharmacology , DNA/biosynthesis , Gene Expression , Humans , Insulin/pharmacology , Mice , Molecular Sequence Data , Phosphorylation , Receptor, Insulin/metabolism , Recombinant Proteins , Sequence Alignment , alpha-2-HS-Glycoprotein , alpha-Fetoproteins/chemistry , alpha-Fetoproteins/pharmacologyABSTRACT
Uptake by the liver of the organic cation and essential nutrient choline is required for the hepatic synthesis of phosphatidylcholine. Uptake of other organic cations is also important for the metabolism and secretion of numerous endobiotics and drugs. Although a high affinity mammalian hepatic choline transporter has been kinetically defined, it has not been previously identified. We have developed stable transfectants of BALB/3T3 cells, using a murine member of the organic cation transporter gene family (mOct1/Slc22a1), and used these cells to characterize the transport of the organic cation choline and model organic cation tetraethylammonium (TEA). Functional expression of mOct1/Slc22a1 in BALB/3T3 cells confers the saturable, temperature-dependent uptake of choline with a K(m) of 42 micrometer, and uptake of TEA with a K(m) of 43 micrometer. We subsequently used our cell culture uptake system to kinetically define in HepG2 cells a high affinity choline uptake process, which transports choline with a K(m) similar to that of mOct1/Slc22a1 protein. We also demonstrated that organic cation transport by mOct1/Slc22a1 is inhibited by several organic cations, and that the gene is expressed in the perinatal period, at a time when phosphatidylcholine synthesis increases. We conclude that mOct1/Slc22a1 encodes a high affinity mammalian hepatic choline/organic cation transporter. This transporter may be important for hepatic phosphatidylcholine synthesis, and for the metabolism and secretion of many organic cationic drugs.
Subject(s)
Carrier Proteins/genetics , Choline/metabolism , Liver/metabolism , Membrane Proteins/genetics , 3T3 Cells , Animals , Biological Transport , Carrier Proteins/metabolism , Cell Line , Humans , Kinetics , Membrane Proteins/metabolism , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Organic Cation Transporter 1 , Tetraethylammonium/metabolism , TransfectionABSTRACT
We have previously shown that noninfected human T-cell lines express the canonical 5.7 kb mRNA coding for the type beta platelet-derived growth factor-receptor (PDGF beta-receptor), whereas HTLV-I-infected T-cell lines express a novel PDGF beta-receptor mRNA of 3.8 kb. In this report, we have extended those studies to molecularly characterize the 3.8 kb PDGF beta-receptor mRNA and show that it has resulted from integration of an apparently undeleted HTLV-I provirus into the PDGF beta-receptor gene in an orientation enabling expression of a truncated PDGF beta-receptor mRNA using the 3' HTLV-I long terminal repeat as a promoter. Further, NIH3T3 cells transfected with a plasmid containing the truncated PDGF beta-receptor ORF plasmid generate colonies in soft agar with more cells per colony than untransfected cells, or cells transfected with the Tax 1 or PDGF-B (c-sis) plasmids. These results indicate that the truncated PDGF beta-receptor protein acquires transforming capability and that HTLV-I-induced truncation of PDGF beta-receptor may correlate with HTLV-I-associated neoplasia of human T-cells.
Subject(s)
Cell Transformation, Neoplastic/genetics , DNA, Viral/metabolism , Human T-lymphotropic virus 1/genetics , Protein-Tyrosine Kinases/genetics , Proviruses/genetics , Receptors, Platelet-Derived Growth Factor/genetics , T-Lymphocytes/virology , Virus Integration , 3T3 Cells , Amino Acid Sequence , Animals , Base Sequence , Blotting, Northern , Cell Line, Transformed , Cloning, Molecular , DNA Probes , DNA, Complementary/genetics , Humans , Mice , Molecular Sequence Data , Plasmids/physiology , Protein-Tyrosine Kinases/physiology , Receptor, Platelet-Derived Growth Factor beta , Sequence Analysis, DNA , T-Lymphocytes/enzymology , T-Lymphocytes/physiologyABSTRACT
Immunosurgery is a useful technique for the isolation of inner cell masses from murine blastocysts. Conventionally, rabbit antisera made ad hoc against murine splenic or fetal cells or fibroblasts have been used as antibody sources. We investigated the feasibility of using commercially available rabbit antiserum to murine erythrocytes (anti-RBC) and compared it with rabbit antiserum generated ad hoc to murine L-cells (anti-L-cell). Our results indicate that anti-RBC is at least as effective as anti-L-cell serum for the immunosurgical isolation of inner cell masses, which became either mini-blastocysts (later forming outgrowths) or embryoid bodies (undergoing ectoderm-endodermlike differentiation within 48 h). Because anti-RBC is commercially available, the technical modification described herein increases the accessibility of the immunosurgical protocol for the isolation of murine inner cell masses.